| Item Type | Name |
|
Academic Article
|
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.
|
|
Academic Article
|
Imatinib effect on growth and signal transduction in polycythemia vera.
|
|
Concept
|
Proto-Oncogene Proteins c-myc
|
|
Concept
|
Proto-Oncogene Proteins c-pim-1
|
|
Concept
|
Proto-Oncogene Proteins c-bcl-2
|
|
Concept
|
Proto-Oncogene Proteins pp60(c-src)
|
|
Concept
|
Proto-Oncogene Proteins c-bcr
|
|
Concept
|
Proto-Oncogene Proteins c-jun
|
|
Concept
|
Proto-Oncogene Proteins p21(ras)
|
|
Concept
|
Proto-Oncogene Proteins c-mdm2
|
|
Concept
|
Proto-Oncogene Proteins c-met
|
|
Concept
|
Proto-Oncogene Proteins
|
|
Concept
|
Proto-Oncogene Proteins c-abl
|
|
Concept
|
Proto-Oncogene Proteins c-kit
|
|
Concept
|
Proto-Oncogene Proteins c-akt
|
|
Academic Article
|
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
|
|
Academic Article
|
Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
|
|
Academic Article
|
Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase.
|
|
Academic Article
|
Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.
|
|
Academic Article
|
Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.
|
|
Academic Article
|
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.
|
|
Academic Article
|
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
|
|
Academic Article
|
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
|
|
Academic Article
|
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
|
|
Academic Article
|
Novel approaches in the treatment of systemic mastocytosis.
|
|
Academic Article
|
Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors.
|
|
Academic Article
|
Sequencing of subcloned PCR products facilitates earlier detection of BCR-ABL1(T315I) and other mutants compared to direct sequencing of the ABL1 kinase domain.
|
|
Academic Article
|
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
|
|
Academic Article
|
Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis.
|
|
Academic Article
|
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.
|
|
Academic Article
|
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a.
|
|
Academic Article
|
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
|
|
Academic Article
|
The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling.
|
|
Academic Article
|
The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia.
|
|
Academic Article
|
Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome.
|
|
Academic Article
|
Imatinib mesylate causes hypopigmentation in the skin.
|
|
Academic Article
|
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
|
|
Academic Article
|
T-cell prolymphocytic leukemia: a single-institution experience.
|
|
Academic Article
|
Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour.
|
|
Academic Article
|
The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors.
|
|
Academic Article
|
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
|
|
Academic Article
|
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
|
|
Academic Article
|
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.
|
|
Academic Article
|
Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.
|
|
Academic Article
|
Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?
|
|
Academic Article
|
Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
|
|
Academic Article
|
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
|
|
Academic Article
|
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
|
|
Academic Article
|
Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy.
|
|
Academic Article
|
Farnesyl transferase inhibitor R115777 in myelodysplastic syndrome.
|
|
Academic Article
|
Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.
|
|
Academic Article
|
BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
|
|
Academic Article
|
C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome.
|
|
Academic Article
|
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
|
|
Academic Article
|
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.
|
|
Academic Article
|
Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
|
|
Academic Article
|
MYC protein expression is an important prognostic factor in acute myeloid leukemia.
|
|
Academic Article
|
Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.
|